{"id":"W2969583663","doi":"10.1002/jbm4.10230","title":"Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva‐Derived Endothelial Cells","year":2019,"lang":"en","type":"article","venue":"JBMR Plus","topic":"Heterotopic Ossification and Related Conditions","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eshelman Institute for Innovation, University of North Carolina at Chapel Hill; Nederlandse Federatie van Universitair Medische Centra; Ministero dello Sviluppo Economico; Merck Sharp and Dohme; AFM-Téléthon; Novartis Pharma; Canada Foundation for Innovation; AO Foundation; Wellcome Trust; Fundação de Amparo à Pesquisa do Estado de São Paulo; Genome Canada; Ontario Ministry of Economic Development and Innovation; Innovative Medicines Initiative; Cancer Genomics Centre; Diamond Light Source; Instituto de Salud Carlos III; Boehringer Ingelheim; Takeda Pharmaceutical Company; AbbVie; European Federation of Pharmaceutical Industries and Associations; Janssen Pharmaceuticals; Merck KGaA; Pfizer","keywords":"Fibrodysplasia ossificans progressiva; Activin receptor; Ossification; Mesenchymal stem cell; Heterotopic ossification; Cancer research; Cell biology; Bone morphogenetic protein; Signal transduction; Bone morphogenetic protein 2; BMPR2; Myositis ossificans; Medicine; Bioinformatics; Chemistry; Biology; Pathology; Biochemistry; Anatomy; Gene; In vitro","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007878551,0.0001283967,0.0002497333,0.0001002328,0.00009792408,0.00001412364,0.0000709143,0.000131551,0.0002573085],"category_scores_gemma":[0.00001769966,0.0001079616,0.0001022219,0.0001076241,0.00006064156,0.00004550799,0.00002227297,0.0001142934,0.00007555879],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001221075,"about_ca_system_score_gemma":0.0004220438,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00000583132,"about_ca_topic_score_gemma":0.000002636863,"domain_scores_codex":[0.9989516,0.00001686526,0.0003950896,0.0002314652,0.0001820923,0.0002228836],"domain_scores_gemma":[0.9993571,0.00003549903,0.0001552438,0.0002398523,0.00009340254,0.0001188939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001095767,0.0001308602,0.0006710661,0.0002245692,0.0000709267,0.000005705834,0.001236846,0.00002414439,0.9931262,0.0001624689,0.0001303057,0.004107293],"study_design_scores_gemma":[0.003466581,0.0001131441,0.00176628,0.0002946153,0.00007154566,0.00001743123,0.0005233116,0.001924888,0.9690122,0.00002682265,0.02260859,0.0001746037],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957075,0.00003326923,0.0006672727,0.0001928397,0.0004273283,0.001429217,0.00004840837,0.00005131312,0.001442922],"genre_scores_gemma":[0.9778469,0.000003261109,0.01990856,0.00006590309,0.0001085922,0.00008272514,0.00005824331,0.00002343588,0.001902341],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02411405,"threshold_uncertainty_score":0.4402544,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02781488964846976,"score_gpt":0.3014132759288842,"score_spread":0.2735983862804145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}